← Eichor
Condition: Cdk4 6 Inhibitors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cdk4 6 Inhibitors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer
Phase N/A · 1 location(s) · Julia Foldi · NCT06666439A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06947811Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-
NA · 5 location(s) · Jules Bordet Institute · NCT06925984CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT07366112Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
Phase 2 · 1 location(s) · Seoul National University Hospital · NCT05536128Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormon
Phase N/A · 24 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06805812Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06363734CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients
Phase 3 · 1 location(s) · Fudan University · NCT07019363CDK4/6 Inhibitors in Breast Cancer Elderly Patients: an Observational Ambispective Longitudinal Multicenter Study
Phase N/A · 1 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07399808Prognostic and Predictive Role of Intrinsic Molecular Subtypes in BRCA-associated Breast Cancer
Phase N/A · 6 location(s) · Angela Toss · NCT07617025Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast
Phase 3 · 12 location(s) · Region Örebro County · NCT06044623CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
Phase N/A · 1 location(s) · RenJi Hospital · NCT05795335Real-world Studies of CDK4/6 Inhibitors
Phase N/A · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07407439Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
Phase N/A · 1 location(s) · Wenjin Yin · NCT07180056Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in
NA · 1 location(s) · Azienda Sanitaria Locale di Asti · NCT07524829Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
Phase 2 · 1 location(s) · University of California, San Diego · NCT07227233Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Phase 3 · 99 location(s) · MedSIR · NCT06382948Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors
Phase N/A · 1 location(s) · Roswell Park Cancer Institute · NCT04526587Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer
Phase N/A · 1 location(s) · Institute of Oncology Ljubljana · NCT06650423BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Phase 3 · 74 location(s) · BeOne Medicines · NCT07492641Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07258108Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-L
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07037199Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Phase 3 · 284 location(s) · AstraZeneca · NCT04862663A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Brea
Phase 3 · 60 location(s) · Jiangsu Simcere Pharmaceutical Co., Ltd. · NCT06680921Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
Phase 2 · 13 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT06207734Aspects of Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients - Focusing on Geriatric Screening
Phase N/A · 5 location(s) · Region Jönköping County · NCT07273357Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:
Phase N/A · 18 location(s) · European Institute of Oncology · NCT07180693Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
Phase N/A · 1 location(s) · Hunan Cancer Hospital · NCT06033287To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
Phase N/A · 1 location(s) · Fondazione Sandro Pitigliani · NCT04660435Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastat
NA · 1 location(s) · Washington University School of Medicine · NCT04968964
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.